Noxopharm Limited
NOXOF · OTC
6/30/2024 | 12/30/2023 | 6/30/2023 | 12/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.04 | -0.01 | 0.11 |
| FCF Yield | -14.29% | 11.08% | -62.65% | -2.39% |
| EV / EBITDA | -5.02 | -12.53 | -4.05 | -16.57 |
| Quality | ||||
| ROIC | 601.69% | -35.11% | -27.41% | -14.83% |
| Gross Margin | -63.53% | 99.86% | -82.10% | -73.20% |
| Cash Conversion Ratio | 2.61 | -0.86 | 0.86 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.51% | 12.77% | 34.83% | 43.23% |
| Free Cash Flow Growth | -232.01% | 125.94% | -509.79% | -4.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.67 | 4.57 | 1.20 | 4.06 |
| Interest Coverage | -871.61 | -130.98 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 2.73 |
| Cash Conversion Cycle | -19.92 | -14,395.54 | 394.45 | 177.90 |